Rigel Pharmaceuticals to Enhance Investor Engagement at Piper Sandler Healthcare Conference Presentation

### Rigel Pharmaceuticals Enhances Investor Engagement Through Upcoming Presentation

Rigel Pharmaceuticals, Inc. is set to present an overview of its innovative work at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. Chief Financial Officer Dean Schorno will lead the presentation at 8:30 am ET, showcasing the company's ongoing commitment to developing groundbreaking therapies for hematologic disorders and cancer. This initiative reflects Rigel's proactive approach in fostering transparency and engagement with the investment community, an essential aspect of its operational ethos. The live webcast and archived recording will be accessible via Rigel's Investor Relations section, emphasizing the company’s dedication to keeping stakeholders informed about its advancements.

Founded in 1996, Rigel Pharmaceuticals is deeply committed to enhancing patient lives through its innovative pipeline and marketed products. The company specializes in the development of novel therapies specifically targeting hematologic disorders and various forms of cancer, areas that have historically posed significant challenges in treatment efficacy and patient outcomes. By participating in prominent healthcare conferences, Rigel not only highlights its scientific advancements but also reinforces its role as a leader in biopharmaceutical innovation. The presentation at the Piper Sandler Conference is an opportunity to engage with healthcare professionals, investors, and analysts, thereby enhancing the visibility of its therapeutic solutions.

The announcement of Schorno's presentation comes at a crucial time as Rigel continues to build on its portfolio of novel therapies. The company’s strategic focus on hematology and oncology positions it well within the competitive landscape of biotechnology. By prioritizing these therapeutic areas, Rigel aims to address unmet medical needs and improve treatment outcomes for patients suffering from serious health conditions. As the company prepares for its upcoming presentation, industry observers are keen to see how Rigel's innovative approaches will be showcased and the potential impacts on future collaborations and investments.

In addition to the upcoming conference presentation, Rigel Pharmaceuticals encourages interested parties to connect in advance for software downloads needed to access the webcast. The company remains accessible for inquiries, with investors directed to a dedicated contact line, while media inquiries are routed through Argot Partners. This level of engagement underscores Rigel's commitment to maintaining open lines of communication with both the investment community and the media, further solidifying its position as a key player in the biotechnology sector.